Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma 2Leukemia 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Leukemia, Lymphoid 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 34fludarabine phosphate 33Cytarabine 33fludarabine 26Peripheral Blood Stem Cell Transplantation 23Filgrastim 23Methotrexate 18Busulfan 17Rituximab 15Cyclosporine 14Azacitidine 14Melphalan 13Clofarabine 13Tacrolimus 12venetoclax 11Mycophenolic Acid 10Etoposide 10Alemtuzumab 10Radiotherapy 9Imatinib Mesylate 8Granulocyte Colony-Stimulating Factor 8Decitabine 8ruxolitinib 7Whole-Body Irradiation 7Stem Cell Transplantation 7Idarubicin 7Dexamethasone 7Antilymphocyte Serum 7aldesleukin 6Mitoxantrone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia × forodesine × Clear all
NCT00289562 2012-01-20

Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia

BioCryst Pharmaceuticals

Phase 1/2 Completed
20 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoma

NCT00035022 2006-01-13

Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

BioCryst Pharmaceuticals

Phase 1/2 Completed
71 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡